Your browser doesn't support javascript.
loading
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020.
Orru', Stefano; Bierbaum, Sibylle; Enk, Alexander; Hengel, Hartmut; Hoffelner, Marcus; Huzly, Daniela; Keller-Stanislawski, Brigitte; Mahler, Vera; Mockenhaupt, Maja; Oberle, Doris.
Afiliação
  • Orru' S; Division of Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut, Langen, Germany.
  • Bierbaum S; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Enk A; Department of Microbiology, Virology and Hygiene, Institute of Virology, Medical Center, University of Freiburg, Freiburg, Germany.
  • Hengel H; German Consulting Laboratory for HSV and VZV, Medical Center, University of Freiburg, Freiburg, Germany.
  • Hoffelner M; Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Huzly D; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Keller-Stanislawski B; Department of Microbiology, Virology and Hygiene, Institute of Virology, Medical Center, University of Freiburg, Freiburg, Germany.
  • Mahler V; German Consulting Laboratory for HSV and VZV, Medical Center, University of Freiburg, Freiburg, Germany.
  • Mockenhaupt M; Division of Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut, Langen, Germany.
  • Oberle D; Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Euro Surveill ; 28(50)2023 12.
Article em En | MEDLINE | ID: mdl-38099347
ABSTRACT
BackgroundShortly after the launch of a novel adjuvanted recombinant zoster vaccine (RZV), Shingrix, cases of suspected herpes zoster (HZ) or zoster-like skin reactions following immunisation were reported.AimWe aimed to investigate if these skin manifestations after administration of RZV could be HZ.MethodsBetween April and October 2020, general practitioners (GP) reporting a suspected case of HZ or zoster-like skin manifestation after RZV vaccination to the Paul-Ehrlich-Institut, the German national competent authority, were invited to participate in the study. The GP took a sample of the skin manifestation, photographed it and collected patient information on RZV vaccination and the suspected adverse event. We analysed all samples by PCR for varicella-zoster virus (VZV) and herpes-simplex virus (HSV) and genotyped VZV-positive samples. In addition, cases were independently assessed by two dermatologists.ResultsEighty eligible cases were enrolled and 72 could be included in the analysis. Of the 72 cases, 45 were female, 33 were 60-69 years old, 32 had skin symptoms in the thoracic and 27 in the cervical dermatomes. Twenty-seven samples tested PCR positive for VZV (all genotyped as wild-type, WT), three for HSV-1 and five for HSV-2.ConclusionIt may be difficult to distinguish HZ, without a PCR result, from other zoster-like manifestations. In this study, VZV-PCR positive dermatomal eruptions occurring in the first weeks after immunisation with RZV were due to WT VZV, which is not unexpected as HZ is a common disease against which the vaccine is unlikely to provide full protection at this time.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Herpes Zoster / Herpes Zoster Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Euro Surveill Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Herpes Zoster / Herpes Zoster Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Euro Surveill Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Suécia